Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
Journal of Experimental Medicine, Volume 209, No. 8, Year 2012
Notification
URL copied to clipboard!
Description
Two to three years after infection, a fraction of HIV-1-infected individuals develop serologic activity that neutralizes most viral isolates. Broadly neutralizing antibodies that recognize the HIV-1 envelope protein have been isolated from these patients by single-cell sorting and by neutralization screens. Here, we report a new method for anti-HIV-1 antibody isolation based on capturing single B cells that recognize the HIV-1 envelope protein expressed on the surface of transfected cells. Although far less efficient than soluble protein baits, the cell-based capture method identified antibodies that bind to a new broadly neutralizing epitope in the vicinity of the V3 loop and the CD4-induced site (CD4i). The new epitope is expressed on the cell surface form of the HIV-1 spike, but not on soluble forms of the same envelope protein. Moreover, the new antibodies complement the neutralization spectrum of potent broadly neutralizing anti-CD4 binding site (CD4bs) antibodies obtained from the same individual. Thus, combinations of potent broadly neutralizing antibodies with complementary activity can account for the breadth and potency of naturally arising anti-HIV-1 serologic activity. Therefore, vaccines aimed at eliciting anti-HIV-1 serologic breadth and potency should not be limited to single epitopes. © 2012 Klein et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3409500/bin/supp_209_8_1469__index.html
https://efashare.b-cdn.net/share/pmc/articles/PMC3409500/bin/supp_jem.20120423_JEM_20120423_sm.pdf
Authors & Co-Authors
Klein, Florian
United States, New York
Rockefeller University
Gaebler, Christian
United States, New York
Rockefeller University
Germany, Dresden
Medizinische Fakultät Carl Gustav Carus
Mouquet, Hugo
United States, New York
Rockefeller University
Sather, D. Noah
United States, Seattle
Seattle Biomedical Research Institute
Lehmann, Clara
Germany, Koln
Uniklinik Köln
Scheid, Johannes F.
United States, New York
Rockefeller University
Germany, Berlin
Charité – Universitätsmedizin Berlin
Kraft, Zane
United States, Seattle
Seattle Biomedical Research Institute
Liu, Yan
United Kingdom, London
Imperial College London
Pietzsch, John
United States, New York
Rockefeller University
Hurley, Arlene M.
United States, New York
Rockefeller University
Poignard, Pascal
United States, San Diego
Scripps Research Institute
Feizi, Ten
United Kingdom, London
Imperial College London
Morris, Lynn
South Africa, Johannesburg
National Institute for Communicable Diseases
Walker, Bruce D.
United States, Cambridge
Massachusetts Institute of Technology
Fätkenheuer, Gerd
Germany, Koln
Uniklinik Köln
Seaman, Michael S.
United States, Boston
Beth Israel Deaconess Medical Center
Stamatatos, Leonidas L.
United States, Seattle
Seattle Biomedical Research Institute
Nussenzweig, Michel C.
United States, New York
Rockefeller University
Statistics
Citations: 168
Authors: 18
Affiliations: 10
Identifiers
Doi:
10.1084/jem.20120423
ISSN:
00221007
e-ISSN:
15409538
Research Areas
Infectious Diseases